Valuation: Carmat SA

Market Cap 6.15M 6.99M 5.74M 5.26M 9.86M 670M 10.1M 68.03M 26.6M 332M 26.26M 25.69M 1.15B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 67.42M 55.3M 50.75M 95M 6.46B 97.35M 656M 256M 3.2B 253M 248M 11.05B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.08
Extreme 0.085
0.59
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
44.95
Manager TitleAgeSince
Chief Executive Officer 55 31/08/2016
Director of Finance/CFO - 11/12/2018
Chief Tech/Sci/R&D Officer - 31/03/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 01/01/2017
Director/Board Member 79 19/04/2017
Date Insider Type Main position Quantity % Market Cap.
13/03/25 Sell

Chairman

1,343,333 2.3347%
13/03/25 Buy

Chairman

1,343,333 2.3347%
29/05/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-68.47%-98.69% 7.08M
+1.63%+13.91%-12.06%+24.29% 133B
+1.21%+8.00%+3.71%+2.19% 13.43B
+6.83%+5.76%+72.42%+109.57% 8.88B
-1.27%+4.27%-44.88%-69.82% 4.71B
+2.18%+0.25%+0.54%+38.53% 2.63B
+2.51%+13.97%+10.76%-52.64% 1.7B
+3.47%+1.44%-15.85%-23.38% 1.62B
+2.35%+3.25%-24.63%-33.29% 1.61B
Average +2.10%+2.79%-8.72%-11.47% 18.61B
Weighted average by Cap. +1.37%+4.99%-6.97%+22.82%

Financials

2023 2024
Net sales 3.84M 4.37M 3.58M 3.29M 6.15M 418M 6.3M 42.47M 16.61M 207M 16.39M 16.04M 715M 7.34M 8.36M 6.86M 6.29M 11.78M 801M 12.07M 81.29M 31.79M 396M 31.38M 30.7M 1.37B
Net income -53.87M -61.31M -50.28M -46.15M -86.38M -5.87B -88.51M -596M -233M -2.91B -230M -225M -10.05B -51.4M -58.49M -47.97M -44.03M -82.42M -5.6B -84.45M -569M -222M -2.77B -220M -215M -9.58B
Net Debt 49.64M 56.49M 46.33M 42.52M 79.59M 5.41B 81.56M 549M 215M 2.68B 212M 207M 9.26B 53.1M 60.43M 49.56M 45.49M 85.15M 5.79B 87.25M 588M 230M 2.86B 227M 222M 9.9B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock